Brexit Effect on Biosimilar


The negative tendency of biosimilars Brexit impact. The hindrance towards the value cutting approach taken by the NHS may be a major setback towards approval and launch of biosimilars in market. With Britain being among foremost clinical preliminary focuses is claimed to ascertain a diminishing within the eagerness of the manufacturers and specialists to try to to any longer preliminaries in Britain. Additionally, Brexit will cause the first rationale of British Biosimilars Association (BBA) to fall back-which went for expanding the use of Biosimilars.


  • No Tariffs or Quotas
  • Life Sciences Investment
  • The

Related Conference of Brexit Effect on Biosimilar

December 01-02, 2025

13th International Conference on Clinical Trials

Vancouver, Canada
January 29-30, 2026

19th World Drug Delivery Summit

Paris, France
February 10-11, 2026

40th World Congress on Pharmacology and Therapeutics

Barcelona, Spain
February 23-24, 2026

3rd World Congress on Biologics and Biosimilars

London, UK
March 23-24, 2026

36th Annual European Pharma Congress

London, UK
March 24-25, 2026

11th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
April 16-17, 2026

19th European Biosimilars Congress

Rome, Italy
April 27-28, 2026

9th European Biopharma Congress

Paris, Aland Islands
May 28-29, 2026

3rd International Conference on Pharmacognosy

Madrid, Spain
July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France

Brexit Effect on Biosimilar Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in